Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Stock Information for Lyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lyra Therapeutics Inc.

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.